Dresden/Germany (ots) - The international scientific community is called to submit applications for the premiere of the world's first award for cutting edge contributions to the progress of life sciences through lipidomics, the 2019 "Lipidomics Excellence Award" (LEA) until 30 March, 2019. Prof. Dr. Kai Simons, ...
Hamburg, Germany (ots) - Recent data published in Annals of Oncology (https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy417/5139593) from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA (ctDNA) may offer clinicians higher-resolution information ...
Hamburg, Germany (ots) - Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups demonstrate the importance of a highly sensitive test for detection of clinically-relevant mutations present in circulating tumor DNA (ctDNA) derived ...
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...
European Society for Medical Oncology (ESMO)
Lugano/Munich (ots) - Twitter is a place where many cancer patients share and discuss their experiences, a study at the ESMO 2018 Congress reveals, based on analysis of the contents of over 6,000 tweets and retweets about breast cancer. The study was part of a larger, multidisciplinary project to observe the presence of different diseases on social media. The data ...
New Delhi (ots) - Ministers and sanitation sector leaders from around the world will convene this month at the Mahatma Gandhi International Sanitation Convention (MGISC) in New Delhi. Hosted by the Government of India, this event will be an opportunity for delegates to exchange sanitation successes and best ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - - Indication: Picture can be downloaded free of charge under: http://www.presseportal.ch/de/nr/100006433?langid=2 - At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. ESMO advocated the strengthening of health systems to achieve Universal Health Coverage and to provide ...
Hitachi Medical Systems Europe Holding AG
Vienna (ots) - - Indication: Picture can be downloaded free of charge under: http://www.presseportal.ch/de/nr/100012989?langid=2 - This function enables the operation of the diagnostic ultrasound system via auto detection of transducer movement. Hitachi Medical Systems Europe, a wholly owned subsidiary of Hitachi, ...
Vienna/Rengsdorf (ots) - In January 2018, a change in the Executive Board of manufacturer and supplier of medical devices, Lohmann & Rauscher (L&R), took place after the former Chief Commercial Officer, Markus Sebastian, had resigned. The Advisory Board and the CCO mutually agreed that Markus Sebastian is going to leave the Lohmann & Rauscher Corporate Group by the end of January 2018 to pursue new tasks and face new ...
UMIT - The Health & Life Sciences University
Ingelheim, Germany (ots/PRNewswire) - - Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20% - Head and neck cancer has a very poor prognosis with no ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], ...
Ingelheim, Germany, November 16 (ots/PRNewswire) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at ...
Ingelheim, Germany (ots/PRNewswire) - - New Formulation Brings the Established Efficacy of Mirapexin(R)/Sifrol(R) to Patients With Parkinson's Disease in the Convenience of a Once Daily Dose Boehringer Ingelheim today announced that the Mirapexin(R)/Sifrol(R) (pramipexole) new prolonged-release , once daily tablet ...
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The company confirmed that first results from the Phase III clinical ...
Ingelheim, Germany (ots/PRNewswire) - - Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC) INGELHEIM, Germany, August 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International ...
Cape Town, South Africa (ots/PRNewswire) - - For Medical Media Outside the US Only Results from the ARTEN* trial presented at the 5th International AIDS Society (IAS) conference in Cape Town, South Africa demonstrated non-inferiority regarding efficacy between Viramune(R) (nevirapine) and ritonavir boosted ...
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media Outside the US only Boehringer Ingelheim announced today that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for VIRAMUNE(R) (nevirapine) in the treatment of patients with HIV. The decision followed a positive recommendation by the Committee for Medical Products ...
Ingelheim, Germany (ots/PRNewswire) - - For non-U.S. Healthcare Media Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending the approval of a once daily formulation for Mirapexin(R) / ...
Ingelheim, Germany (ots/PRNewswire) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual ...
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan Boehringer Ingelheim announced today that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke professionals being developed by the World Stroke Organization (WSO). ...
Ingelheim, Germany (ots/PRNewswire) - - New Study Shows That Mirapexin(R)/Sifrol(R) (Pramipexole) Relieves Depressive Symptoms of Parkinson's Disease (PD), a Common Non-Motor Symptom Affecting PD Patients' Quality of Life - For Non-US Healthcare Media To view the Multimedia News Release, go to: ...
Ingelheim, Germany (ots/PRNewswire) - - Data for the Once Daily Mirapexin(R)/Sifrol(R) (Pramipexole) Formulation Under Development Show Efficacy, Safety and Tolerability Outcomes Comparable to the Current Immediate Release Formulation for the Treatment of Parkinson's Disease For non-US Healthcare Media First data ...
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media outside the U.S.A. New data presented today at the 61st Annual Meeting of the American Academy of Neurology (AAN), in Seattle, U.S.A. show that augmentation did not significantly differ in RLS patients treated with Mirapexin(R) /Sifrol(R) (pramipexole*) ...
Ingelheim, Germany (ots/PRNewswire) - - Unique Educational Website 'Under the Covers of Restless Legs Syndrome (RLS)' is Launched on World Sleep Day - For Non-US Healthcare Media The website http://www.rlsunderthecovers.com brings together leading medical experts in the field of Restless Legs Syndrome (RLS) who have undertaken to explain key facts and symptoms of this ...
Ingelheim, Germany (ots/PRNewswire) - - ESO Recommends Extended Time Window for Actilyse(R) INGELHEIM, Germany, January 30 /PRNewswire/ -- - For Healthcare Media outside the U.S.A., Canada, and Japan Based on key results from the European Cooperative Acute Stroke Study (ECASS 3), the European Stroke Organisation (ESO) now recommends that Actilyse(R) (alteplase) be ...
